Article Sidebar
Views pdf: 0
TREATMENT OUTCOMES OF ADVANCED HEPATOCELLULAR CARCINOMA USING LENVATINIB AT BACH MAI HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the treatment outcomes of hepatocellular carcinoma (HCC) patients receiving Lenvatinib at Bach Mai Hospital. Methods: A descriptive, retrospective study on 47 patients with a confirmed diagnosis of HCC who were treated with Lenvatinib at the Nuclear Medicine and Oncology Center – Bach Mai Hospital from March 2022 to March 2025. Results: The disease was most prevalent in the 60–79 age group (53,2%), with the majority being male (89,4%). Most patients had a history of hepatitis B virus infection (80,9%). The proportion of patients with portal vein thrombosis was 23,4%. The objective response rate (ORR) was 51,1%, and the disease control rate (DCR) was 89,4% according to mRECIST 1.1 criteria. The median progression-free survival (PFS) was 6,8 ± 1,0 months. Factors influencing PFS included baseline AFP level and major vascular invasion. The median overall survival (OS) was 10,3 ± 0,8 months. Conclusion: HCC primarily occurred in male patients with a history of hepatitis B virus infection. Most patients in the study had good performance status and preserved liver function. Lenvatinib demonstrated good efficacy and acceptable safety in the treatment of HCC
Article Details
Keywords
Lenvatinib, hepatocellular carcinoma, treatment efficacy.
References
2. Kudo, M. (2018). Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma. Liver Cancer, 7(3), 215–224.
3. Nguyễn Công Long, & Lưu Minh Diệp (2022). Đánh giá giai đoạn ung thư biểu mô tế bào gan theo phân loại Barcelona và một số yếu tố liên quan đến nguyên nhân ung thư gan tại bệnh viện Bạch Mai. Tạp Chí Y học Việt Nam, 514(2). https://doi.org/10.51298/ vmj. v514i2.2622.
4. Hoàng Ngọc Tấn và cộng sự. (2024). Đánh giá kết quả và tính an toàn liệu pháp Lenvatinib bước 01 trên người bệnh đối với ung thư biểu mô tế bào gan không thể phẫu thuật. VMJ, 536(2).
5. Kudo M, Ueshima K, Chan S, et al. (2019). Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers (Basel), 11(8): 1084. doi:10.3390/ cancers11081084.
6. Ueshima, K., Nishida, N., Hagiwara, S., et al (2019). Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study. Cancers, 11(7), 952.
7. Lee, S.-W., Yang, S.-S., Lien, H.-C., Peng, Y.-C., Ko, C.-W., & Lee, T.-Y. (2022). Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population. Journal of Clinical Medicine, 11(5), 1444.
8. Welland, S., Leyh, C., Finkelmeier, F., Jefremow, A.,et al. (2022). Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study. Liver cancer, 11(3), 219–232. https://doi. org/10.1159/000521746.
9. Goh M.J., Oh J.H., Park Y., et al. (2021). Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a RealWorld Practice in Korea. LIC, 10(1), 52–62.